Cramer on big pharma: Sell

Mad money man Jim Cramer last week articulated his view of the giants in the pharma industry. "This is just one expensive graveyard of stocks," he said on his CNBC program.

Cramer cites the usual litany: expiring patents, R&D cuts and tougher FDA drug approvals. But there's another reason, he says. Big pharma is booting the advantage that generics have by increasing the prices of their brand-name drugs to offset losses.

Sell those big pharma stocks, he says, singling out Bristol-Myers Squibb, Eli Lilly, Pfizer, GlaxoSmithKline, Johnson & Johnson and Merck. "The growth and protection is gone from this sector."

- see the summary

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.